Previous Close | 19.26 |
Open | 18.80 |
Bid | 18.45 x 900 |
Ask | 18.49 x 800 |
Day's Range | 17.93 - 18.83 |
52 Week Range | 7.52 - 37.42 |
Volume | |
Avg. Volume | 596,229 |
Market Cap | 870.275M |
Beta (5Y Monthly) | 1.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.05 |
Earnings Date | Oct 12, 2022 - Oct 17, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 37.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for NRIX
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr. Schlezinger is an industry veteran with extensive experience leading and developing human resources at high-growth private and public biopharma companies. “Eric is a proven leader in building and maintaining exceptional compa
In this article, we discuss Cathie Wood’s 10 favorite stock picks for the rest of 2022. If you want to see more stocks in this selection, click Cathie Wood’s 5 Favorite Stock Picks for the Rest of 2022. Cathie Wood, the chief of ARK Investment Management, has been making headlines recently as her hedge fund […]
SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds to sell, in a registered direct offering, pre-funded warrants to purchase 2,869,440 shares of common stock at a price of $13.939 per pre-funded warrant for total gross proceeds of approximately $40 milli